Skip to main content
Clinical Trials/NCT04691011
NCT04691011CompletedNot Applicable

New Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis

Assistance Publique Hopitaux De Marseille1 site in 1 country22 target enrollmentStarted: June 16, 2021Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
22
Locations
1
Primary Endpoint
Disease progression using MRI

Study Overview

Brief Summary

Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Our project aims to find new biomarkers in MRI at three levels: cerebral, medullary and muscular. These markers could allow an earlier diagnosis of the disease by showing more specific lesions of ALS and to quantify these lesions to measure the progression of the disease. This study will use advanced Magnetic Resonance Imaging (MRI) techniques High field (3T) and very high field (7T) MRI. Results from neurological and electrophysiological tests will be compared to the MRI. Subjects will be recruited from ALS center of Marseille, France. MRI will be done on ALS patients at baseline, at 3 month and at 6 month intervals.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Patients will be adults with a diagnosis of ALS.
  • Healthy controls will also be recruited and will be age- and gender-matched to patients.
  • Patients able to undergo a brain MRI for approximately an hour.

Exclusion Criteria

  • Subjects with other psychiatric or CNS or PNS diseases.
  • Subjects ineligible for MRI investigation due to a pacemaker or other metallic foreign body, or significant claustrophobia that could affect the ability to have an MRI scan.

Arms & Interventions

Muscle

Other

Intervention: Muscular MRI (Other)

Muscle

Other

Intervention: Electrophysiological exam (Other)

Spinal cord

Other

Intervention: Muscular MRI (Other)

Spinal cord

Other

Intervention: Electrophysiological exam (Other)

Spinal cord

Other

Intervention: Spinal cord MRI (Other)

Brain

Other

Intervention: Muscular MRI (Other)

Brain

Other

Intervention: Electrophysiological exam (Other)

Brain

Other

Intervention: Brain MRI (Other)

Outcomes

Primary Outcomes

Disease progression using MRI

Time Frame: Change from Baseline and at Month 6

Muscular, brain and spinal cord MRI (brain sodium concentration, muscular volume of members, measure of transversal area for spinal cord)

Secondary Outcomes

  • Alterations of metabolic and funtional brain(Baseline and Month 6)
  • Link between MRI and clinical scales(Baseline and Month 6)
  • Link between MRI and MUNIX(Baseline and Month 6)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials